<DOC>
	<DOCNO>NCT02717923</DOCNO>
	<brief_summary>This single arm , open-label clinical trial evaluate efficacy safety maintenance treatment capecitabine plus cetuximab first-line modify fluorouracil , leucovorin , oxaliplatin ( mFOLFOX6 ) plus cetuximab patient KRAS wild-type metastatic colorectal cancer .</brief_summary>
	<brief_title>A Single Arm , Open-label Clinical Trial Evaluate Efficacy Safety Maintenance Treatment With Capecitabine Plus Cetuximab Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Subjects fully understand research volunteer sign consent form ; 2 . Histologically and/or cytologically diagnose KRAS wildtype metastatic metastatic colorectal cancer ( Phase IV ) , histological type exclude ; 3 . Subjects stable disease well induction treatment eight twelve 2weekly cycle mFOLFOX6 ; 4 . ECOG Performance Status ( ECOG PS ) ≤1 ( 01 ) ; 5 . Evident measurable lesion ( ) meet Response Evaluation Criteria Solid Tumors ( RECIST 1.1 ) ; 6 . Expected survival＞16 week . 1 . Subjects presence clinically detectable second primary malignant tumor enrollment , malignant tumor within last 5 year ( exclude adequately treat skin basal cell carcinoma carcinoma situ cervix ) ; 2 . Clinical refractory disease ( include uncontrolled epilepsy ) , affect survivor ; 3 . Central Nervous System ( CNS ) metastatic disease prior cerebral metastasis ; 4 . Researchers think subject exist clinical laboratory abnormality compliance issue suitable participate clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>metastatic colorectal cancer</keyword>
	<keyword>maintenance treatment</keyword>
	<keyword>cetuximab</keyword>
</DOC>